Skip to main content
Menu
bmp9 variants hero
Literature - Publication Review

Targeting BMPR2 signaling in pulmonary arterial hypertension with wild-type and non-osteogenic BMP9 variants

This publication review examines research on wild-type BMP9 and a non-osteogenic BMP9 variant (A347E) as approaches to modulate BMPR2 signaling in pulmonary arterial hypertension (PAH), using AlphaLISA™ SureFire® Ultra™ assays to assess SMAD pathway activation.

Read the publication review to explore:

  • An overview of BMPR2 signaling in pulmonary arterial hypertension (PAH) and the potential of BMP9-based approaches to modulate this pathway.
  • In vitro and in vivo characterization of wild-type BMP9 and the non-osteogenic A347E variant, including assessment of SMAD1/3 signaling and target gene activation
  • How AlphaLISA SureFire® Ultra assays support the characterization of SMAD signaling in response to wild-type BMP9 and the A347E variant.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
Image CAPTCHA
Get new captcha!

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Targeting BMPR2 signaling in pulmonary arterial hypertension with wild-type and non-osteogenic BMP9 variants

Download Literature - Publication Review

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.

Revvity AI Assistant Beta

Scroll Icon